Research Article
Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenström Macroglobulinemia in Korea
Table 3
Multivariate analysis for response and survival.
| Value | ORR | OS | RR | 95% CI | value | RR | 95% CI | value |
| Age, years | | | | | | | <65 | | | | | | | ≥65 | | | | 1.021 | 0.350–2.980 | 0.970 | ALC, ×109/L | | | | | | | <1.0 | | | | | | | ≥1.0 | 0.362 | 0.060–2.193 | 0.369 | | | | ECOG (%) | | | | | | | 0-1 | | | | | | | ≥2 | 2.006 | 0.711–5.660 | 0.188 | 0.421 | 0.147–1.208 | 0.108 | Serum albumin, g/dL | | | | | | | <3.5 | | | | | | | ≥3.5 | | | | 1.123 | 0.264–4.772 | 0.875 | ISS (%) | | | | | | | I | | | | | | | II | | | | 0.439 | 0.078–2.486 | 0.352 | III | | | | 0.209 | 0.066–0.665 | 0.008 | Treatment regimen | | | | | | | Novel agent combined chemotherapy | | | | | | | Conventional chemotherapy | 5.048 | 1.032–24.702 | 0.046 | 0.368 | 0.075–1.803 | 0.217 |
|
|
ORR: overall response rates; OS: overall survival rates; RR: relative risk; 95% CI: 95% confidence interval; ALC: absolute lymphocyte count; ECOG: Eastern Cooperative Oncology Group performance status; ISS: international staging system.
|